Animal models of leukodystrophy : a new perspective for the development of therapies by Rutherford, H.A. & Hamilton, N.
This is a repository copy of Animal models of leukodystrophy : a new perspective for the 
development of therapies.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/151338/
Version: Accepted Version
Article:
Rutherford, H.A. and Hamilton, N. orcid.org/0000-0002-3299-9133 (2019) Animal models 
of leukodystrophy : a new perspective for the development of therapies. The FEBS 
Journal. ISSN 1742-464X 
https://doi.org/10.1111/febs.15060
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
 1 
Animal Models of Leukodystrophy: A new perspective for the development of 
therapies 
Holly A Rutherford and Noémie Hamilton 
The Bateson Centre, Infection, Immunity and Cardiovascular Disease department, 
University of Sheffield, Firth Court D31, Sheffield S10 2TN 
 
Running Title: New and old models of leukodystrophy: the rise of zebrafish  
 
Keywords: Leukodystrophy, neuroinflammation, animal models, myelin, X-linked 
adrenoleukodystrophy, metachromatic leukodystrophy, Krabbe’s disease, Aicardi-
Goutières syndrome, Alexander disease, zebrafish 
 
Abbreviations 
AAV, adeno-associated viruses; AD, Alexander Disease; AGS, Aicardi-Goutières 
Syndrome; ASA, arylsulfatase A; BBB, blood brain barrier; CNS, central nervous 
system; CRISPR, clustered regularly interspaced short palindromic repeats; ERT, 
enzyme replacement therapy; GALC, galactoceramidase; GFAP, glial fibrillary acidic 
protein; HSCT, haematopoietic stem cell transplantation; KD, Krabbe’s disease; MLD, 
metachromactic leukodystrophy; MRI, magnetic resonance imaging; TALENs, 
transcription activator-like effector nucleases; TREX1, three prime repair exonuclease 
1; VLCFA, very long chain fatty acids; X-ALD, X-linked adrenoleukodystrophy. 
 
 
 
 
 
 2 
 
Abstract 
The leukodystrophies are a family of heritable disorders characterised by white matter 
degeneration, accompanied by variable clinical symptoms including loss of motor 
function and cognitive decline. Now thought to include over fifty distinct disorders, 
there are a vast array of mechanisms underlying the pathology of these monogenic 
conditions and, accordingly, a range of animal models relating to each disorder. While 
both murine and zebrafish models continue to aid in the development of potential 
therapies, many of these models fail to truly recapitulate the human condition—thus 
leaving substantial weaknesses in our understanding of leukodystrophy pathogenesis. 
Additionally, the heterogeneity in leukodystrophy presentation—both in patients and 
in vivo models—often results in a narrow focus on single disorders in isolation across 
much of the literature. Thus, this review aims to synthesise prominent research 
regarding the most common leukodystrophies in order to provide an overview of key 
animal models and their utility in developing novel treatments. We begin by discussing 
the ongoing revolution across the leukodystrophy field following the rise of next 
generation sequencing, before focusing more extensively on existing animal models 
from the mouse and zebrafish fields. Finally, we explore how these pre-clinical models 
have shaped the development of therapeutic strategies currently in development. We 
propose future directions for the field and suggest a more critical view of the dogma 
which has underpinned leukodystrophy research for decades. 
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Introduction 
Derived from the Greek leuko (meaning white) and dystrophy (meaning wasting), 
leukodystrophies are family of heritable disorders characterised by white matter 
degeneration—resulting in variable clinical symptoms including loss of motor function 
and cognitive decline [1]. There are now thought to be over fifty leukodystrophies, 
affecting an estimated 31 to 130  cases per million live births [2–4]. 
 
The term “leukodystrophy”—first coined in 1928—has evolved with our growing 
understanding of these disorders [1]. The first formalised definitions—which 
considered leukodystrophies primarily as myelin disorders—set the tone for decades 
of research: with a narrow focus on pathogenic mechanisms relating to the myelin 
sheath and the oligodendrocytes responsible for its formation [5]. 
 
However, the rise of genetic sequencing—and with it, the ability to molecularly classify 
individual patients—has triggered a much-needed shift in the leukodystrophy field: 
leading to a wider consideration of the white matter components involved in 
pathogenesis [6]. Yet, with greater knowledge comes greater complexity—the number 
of distinct, diagnosable leukodystrophies has increased exponentially in recent years, 
alongside growing heterogeneity in proposed disease mechanisms. As a result, many 
reviews focus on one disorder or therapy at a time—leading to a fragmented 
understanding of pathogenesis across this family of disorders [7–9]. However, there is 
much to be gained from considering the commonalities across the wider 
leukodystrophy field: particularly in exploring the critical role of animal models in 
developing novel therapies. While each animal model is specific to a single disease, 
common limitations may restrict the translational impact of preclinical studies if not 
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properly addressed. Nonetheless, a broad discussion of the advantages and caveats 
of existing animal models is lacking from the field. 
  
Hence, this review aims to synthesise prominent literature regarding animal models of 
the most common leukodystrophies in order to identify future directions in the 
development of therapies. In order to provide a cohesive overview of current animal 
models and their utility in developing new treatments, we focus on the five most 
common leukodystrophies: X-linked adrenoleukodystrophy (X-ALD), metachromatic 
leukodystrophy (MLD), Krabbe’s disease (KD), Alexander disease (AD) and Aicardi-
Goutières syndrome (AGS) (Figure 1) [2]. We present recent advances in discovering 
new cellular drivers of these disorders and discuss how these findings, in combination 
with the development of animal models, have shaped the development of therapies. 
 
The next generation of leukodystrophy research: from oligodendrocytes 
to astrocytes and neuroinflammation.  
 
Given the role of oligodendrocytes in the formation of the myelin sheath, it is perhaps 
unsurprising that early leukodystrophy research focussed almost exclusively on this 
cell type. Indeed, leukodystrophies—by their very nature—are associated with failure 
of normal myelin formation (hypomyelinating diseases) or progressive loss of myelin 
(demyelinating disorders), which can be attributed to oligodendrocyte death. For 
example, metachromatic leukodystrophy (MLD) is a common leukodystrophy 
associated with mutations in arylsulfatase A (ASA)—a lysosomal enzyme responsible 
for the breakdown of a key component of the myelin sheath—which are thought to 
result in substrate accumulation and, thus, oligodendrocyte dysfunction [10]. For many 
decades, such oligodendrocyte- and myelin-centric mechanisms were thought to be 
the primary—and perhaps even the sole—drivers of leukodystrophy pathology. 
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However, as whole exome sequencing has become more widely available, the 
involvement of other white matter components in pathogenesis has become 
increasingly apparent—with leukodystrophies associated with mutations in genes 
extending far beyond those predominantly expressed in oligodendrocytes [6]. 
Accordingly, proposed classification systems now consider the contribution of other 
glia cells to white matter pathology (Figure 1) [11]. 
 
Astrocytes 
Astrocytes play an important role in maintenance of white matter through supporting 
oligodendrocyte progenitor cell differentiation and releasing factors which influence 
myelination [12,13]. Indeed, mutations in astrocyte-specific glial fibrillary protein 
(GFAP) are thought to cause Alexander disease (AD)—with therapies targeting this 
protein showing some promise in patients and animal models, as will later be 
discussed [14,15]. Astrocytic dysfunction is not just limited to AD: mutations in other 
astrocytic gene products have been linked with Megalencephalic 
leukoencephalopathy with subcortical cysts, while severe astrocytic pathology has 
been observed in mouse models and post-mortem tissue from patients with vanishing 
white matter disorder [16,17]. 
 
Microglia and neuroinflammation 
Microglia too are thought to play a role in leukodystrophy pathology: perhaps 
unsurprising, given their roles in supporting myelination, oligodendrocyte progenitor 
cell survival and differentiation and response to white matter damage [18,19]. 
Crucially, as the major innate immune cells within the central nervous system (CNS), 
microglia can also induce oligodendrocyte apoptosis in response to injury [20].  
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While microglial reactivity has long since been considered a consequential component 
of leukodystrophy pathology, recent research has suggested that microglial 
abnormalities may precede myelin loss in several common leukodystrophies. A recent 
post-mortem study of X-linked adrenoleukodystrophy (X-ALD) and metachromatic 
leukodystrophy (MLD) reported reductions in overall microglial number alongside 
increases in activated microglia in areas presenting markers of early white matter 
lesions: suggesting that such changes precede reductions in oligodendrocyte and 
myelin viability [21]. While post-mortem studies are somewhat limited in providing a 
true time-course of pathology progression, it has also been reported that microglial 
activation arises before astrocyte reactivity and myelin loss in mouse models of 
Krabbe’s disease (KD). Strikingly, markers of the innate immune response were 
elevated even before microglial activation [22,23]. Together, these data suggest that 
immune response may be a driver, rather than a consequence, of pathology in some 
leukodystrophies. 
 
Indeed, several leukodystrophies present with phenotypes that mimic congenital 
cytomegalovirus infection, and thus have long-since been considered autoimmune in 
nature: such as Aicardi-Goutières syndrome (AGS) and a rare but similar disorder: 
RNASET2-deficient cystic leukoencephalopathy [24,25]. In these disorders, the innate 
immune response is thought to be triggered by the recognition of self-derived nucleic 
acids as non-self. The above literature suggests that attack of self-derived 
components may underlie pathology beyond disorders traditionally considered to be 
autoimmune. 
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Hence, there are a growing number of proposed mechanisms underpinning 
leukodystrophy pathology—many of which may be shared across multiple disorders. 
However, in order to truly understand leukodystrophy pathogenesis and develop 
effective therapeutic interventions, animal models which recapitulate key aspects of 
human disease are essential. 
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Figure 1: Pathology and clinical manifestations of five common 
leukodystrophies. AD, Alexander disease; AGS, Aicardi-Goutières syndrome; KD, 
Krabbe’s disease; MLD, metachromatic leukodystrophy; VLCFA, very long chain fatty 
acids; X-ALD, X-linked adrenoleukodystrophy [10-29]. 
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Animal models of leukodystrophies 
The heritable nature of leukodystrophies has led to the development of a range of 
monogenic animal models: each specific to a single disorder and, often, failing to 
encapsulate the entirety of the human pathology. While a variety of species have been 
explored as models of these rare diseases, much of the literature focuses on zebrafish 
and, in particular, murine models. 
 
Mouse models 
The mouse model that has shown perhaps the greatest utility to the field is the twitcher 
mouse: a naturally occurring model of Krabbe’s disease (KD) with a mutation in Galc 
(the gene for galactoceramidase, critical for the breakdown of the lipid psychosine). 
While this specific mutation is reported in only a subset of KD patients, these mice 
develop pathology with remarkable similarity to that seen in the human condition: with 
robust central demyelination and gliosis, alongside clinical symptoms typical of KD 
patients and significant reductions in survival [22,26,27]. With such strong face and 
construct validity, the twitcher mouse has allowed us to further our understanding of 
KD pathology—with recent research in this model suggesting that myelin 
abnormalities may begin much earlier in development than previously thought [28]. 
Reduced myelin staining was observed in infant mice long before the surge in 
oligodendrocyte apoptosis characteristic of the twitcher model, alongside impairments 
in oligodendrocyte progenitor cell differentiation in twitcher-derived cells—suggesting 
developmental defects in myelin formation. These findings are the first to suggest that 
perhaps both hypomyelinating and demyelinating mechanisms underpin KD, which 
has long-since been considered demyelinating disease—challenging our 
understanding of pathogenesis. 
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However, naturally occurring models of disease are rare and, as such, the vast 
majority of leukodystrophy models are transgenic, knock-in or knockout animals. Many 
leukodystrophies are associated with loss-of-function mutations: leading to reduced 
levels of functioning or malfunctioning protein. Hence, the most common mouse 
models of these disorders are knockouts of disease-associated genes—such as the 
widely used ASA-deficient model of metachromatic leukodystrophy (MLD), three prime 
repair exonuclease 1 (TREX1)-deficient model of AGS and ABCD1-deficient model of 
X-ALD [29–33] (Table 1, Figure 1). Yet, these models fail to recapitulate human 
disease: lacking key aspects of leukodystrophy neuropathology.  Trex1-/- mice do not 
develop neuroinflammation, while ASA-/- mice present no evidence of demyelination 
until two years-of-age: a significantly slower disease-course relative to the human 
condition [29,30,34]. Similarly, ABCD1-deficient mice also fail to present with myelin 
abnormalities within the brain—despite accumulation of very long chain fatty acids 
(VLCFA) characteristic of the disorder [31–33,35] (Table 1). 
There are also notable limitations to using knockouts as models of leukodystrophy. 
Firstly, complete knockouts have little relevance to the human phenotype—with most 
patients expressing a low level of functioning or malfunctioning protein. Additionally, 
such extreme genotypes present a challenge in investigating therapies that aim to 
reintroduce target proteins, such as gene- or enzyme-replacement therapy, as the 
novel protein can initiate immune response after being recognised as foreign [36]. This 
makes it difficult to predict the efficacy of such treatments in patients, who—having 
some endogenous expression of these genes—will not surmount an immune response 
to such proteins [10].  
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Not all leukodystrophies are associated with loss-of-function mutations: several are 
associated with toxic gain-of-function mutations which can be equally devastating. AD 
is one such disorder: caused by gain-of-function mutations in glial fibrillary acidic 
protein (GFAP)[17]. These mutations are thought to lead to GFAP aggregation—
forming structures known as Rosenthal fibres—and thus astrocytic cell death and 
downstream white matter pathology [37]. To mimic the effects of such gain-of-function 
mutations, knock-in mutations in GFAP have been created in several mouse lines 
[38,39]. However, while these animals develop Rosenthal fibres and astrocyte 
reactivity in a distribution similar to that seen in human patients, this is not 
accompanied by white matter abnormalities or reductions in survival—once again 
failing to truly encapsulate key elements of human pathology. 
 
Table 1: Phenotypes of common mouse models of leukodystrophy 
Model 
Relevant 
disease 
Phenotype Ref. 
twitcher mouse 
Krabbe’s 
disease 
Central demyelination, gliosis, infiltration 
of globoid cells (multinucleated 
macrophages), progressive hindlimb 
weakness, reduced survival 
[26,27] 
ASA knockout 
Metachromatic 
leukodystrophy 
Accumulation of cerebroside-3-sulfate, 
gliosis, neuromotor impairments 
[29] 
TREX1 knockout 
Aicardi-
Goutières 
Syndrome 
Multi-organ inflammation (including 
inflammatory myocarditis), reduced 
survival 
[30,34] 
ABCD1 
knockout 
X-linked 
adreno-
leukodystrophy 
Reduced VLCFA beta-oxidation, 
elevated levels of saturated VLCFA, 
myelin abnormalities at 15 months 
[31–
33,35] 
GFAP knock-in 
mice 
Alexander 
disease 
Formation of Rosenthal fibres, 
increased GFAP expression, astrocyte 
reactivity 
[39] 
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The rise of zebrafish in leukodystrophy research 
Innate immunity studies have shown that there is a significant degree of evolutionary 
conservation between zebrafish and humans [40–43]. The genetic tractability of the 
zebrafish has allowed the generation of multiple fluorescent transgenic lines faithfully 
labelling innate immune cells such as neutrophils and macrophages [44,45]. As such, 
zebrafish surmount a remarkably similar immune response to several pathogens 
compared to humans, such as viruses, mycobacterium and staphylococcus to name 
a few—suggesting the zebrafish by no means invalid as a model of human disease 
(Figure 2) [46–48]. 
Given that many leukodystrophy patients present with infantile or juvenile onset, 
zebrafish provide a unique model system in which to observe the developmental 
component of disease due to their transparency during embryogenesis and early life. 
Additionally, recent developments have facilitated longitudinal observation of 
pathology into adulthood—when the fish become opaque—with magnetic resonance 
imaging (MRI) techniques [49,50]. Indeed, MRI has long since been used to assess 
white matter pathology with high sensitivity in murine models of leukodystrophy—
allowing direct corroboration of findings across all three species of interest (Figure 2) 
[51]. 
 
Due to their small size and ex utero development, zebrafish are also an ideal model 
for high-throughput screening—allowing observation of more complex phenotypes 
than could be seen in cell culture (Figure 2) [52]. Zebrafish embryos are particularly 
useful in the development of drugs for neurological disorders, as the blood brain barrier 
(BBB) does not mature until three to ten days post fertilisation—allowing identification 
of candidate drugs which could potentially be optimised for CNS delivery in humans 
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[53]. Accordingly, the zebrafish is becoming increasingly utilised in neurological 
research to assess the efficacy and toxicity of small molecules in models of epilepsy 
and amyotrophic lateral sclerosis [54,55]. These strategies could easily be applied to 
zebrafish models of leukodystrophy to facilitate relatively simple, low-cost drug 
screens—critical given the rarity of these disorders. 
 
Furthermore, the genetic strategies available to generate zebrafish mutants result in 
genotypes that are largely more relevant to the human conditions. Rather than 
constitutive knockout, anti-sense morpholino approaches are frequently used to 
transiently knockdown expression, while genome editing strategies (such as 
transcription activator-like effector nucleases [TALENs] and clustered regularly 
interrupted short palindromic repeats [CRISPR]/Cas9) have been utilised to generate 
truncated or malfunctioning protein—such that most models are not entirely deficient 
in disease-associated protein. Thus, common zebrafish models not only present with 
a genotype more similar to that of human patients, but also are less likely to surmount 
an aberrant immune response to proteins of interest if therapeutically reintroduced. 
Although fewer in number, zebrafish models reliably present with neurological 
phenotypes (Table 2) therefore increasing their relevance as models of 
leukodystrophy relative to murine models. For example, rnaset2 mutants develop 
white matter lesions in adulthood, and this is accompanied by locomotor and 
behaviour defects in larval and adult stages therefore placing this animal model at the 
forefront of pre-clinical models for leukodystrophy [50,56]. 
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Table 2: Phenotypes of zebrafish models of leukodystrophy 
 
However, it is possible such phenotypes may arise due to off-target effects—to which 
antisense-morpholinos are prone. For example, morpholino-knockdown of zebrafish 
orthologues of GALC led to alterations in neural development without the psychosine 
build-up which is characteristic of KD [57]. While the authors argue that this suggests 
a developmental role for galc which is independent of psychosine-accumulation, it is 
entirely possible the observed phenotype arose due to off-target knockdown effects: 
complicating our understanding of pathogenesis in these models. 
 
Furthermore, not all zebrafish models show white matter-related pathology. While 
some models show reductions in myelin-related proteins and oligodendrocyte number 
(such as degs1 and abcd1 mutants), others display less relevant phenotypes [58,59]. 
Model Relevant disease Phenotype Ref. 
galca/galcb 
knockdown 
Krabbe’s disease 
Disorganised expression of neural 
markers 
[57] 
abcd1 mutant 
X-linked 
adrenoleukodystrophy 
Hypomyelination of spinal cord 
Reduced oligodendrocytes 
Impaired motor function 
Reduced survival 
[59] 
samhd1 
knockdown 
Aicardi-Goutières 
Syndrome 
Cerebral haemorrhage  
Upregulation of innate-immune 
response 
[60] 
degs1 
knockdown 
Hypomyelinating 
leukodystrophy (rare) 
Reduced myelination 
Impaired motor function 
[58] 
rnaset2 
mutant/ 
knockdown 
RNASET2-deficient 
cystic 
leukoencephalopathy 
(rare and similar to 
AGS pathology) 
White matter lesions associated 
with axonal damage and 
astrogliosis 
Behaviour and locomotion defect in 
larvae and adults.  
[50,56] 
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For example, samhd1 knockdown only partially recapitulates AGS phenotype: causing 
brain haemorrhage but not white matter abnormalities [60]. (Table 2). 
 
Thus, there remain few models of leukodystrophy that truly recapitulate human 
pathology. An awareness of the limitations of each model is essential in analysing 
preclinical literature and assessing the effects of potential treatments. 
 
 
 
 
Figure 2: A summary of the general advantages and disadvantages of current 
animal models in leukodystrophy research. 
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Therapies emerging from preclinical models 
Conventional approaches in the treatment of leukodystrophies aim to halt disease 
progression by regaining homeostasis in the CNS—restoring the activity of the 
deficient or malfunctioning protein and thus minimising cell death. Nonetheless, such 
treatments are lacking: failing to reliably alter disease-course and improve survival 
across animal models and patients. Emerging treatments have begun to target 
previously overlooked pathogenic mechanisms—yet, their wider therapeutic benefit 
remains unclear due to limited preclinical testing. In this section, we discuss one such 
treatment—anti-reverse transcriptase therapy—alongside more conventional 
therapies: enzyme replacement therapy, gene therapy, antisense oligonucleotide 
therapy and haematopoietic stem cell transplant. We highlight the role of preclinical 
models in the continuing development of these therapies and suggest future directions 
which may enhance their translational impact (Figure 3). 
 
Enzyme replacement therapy 
First used to treat Gaucher’s disease, enzyme replacement therapy (ERT) has been 
successful in the treatment of several disorders caused by enzymatic dysfunction [61]. 
Enzyme administration can restore enzymatic function within cells, as endocytosis 
mediated by the mannose-6-phosphate receptor allows extracellular enzyme to 
replace its endogenous counterpart [62]. 
 
ERT has been particularly explored in lysosomal storage leukodystrophies – such as 
MLD and KD. Yet, despite strong theoretical rationale, the success of ERT has been 
limited by failure to increase enzyme activity in the CNS: with the blood brain barrier 
(BBB) presenting a significant obstacle for intravenous application.   
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In recent years, however, insightful enzyme delivery strategies have been explored to 
combat this challenge: such as the use of nanoparticles. Due their small size and the 
increasing availability of modifications to optimise drug delivery, nanoparticles are able 
to cross the BBB—presenting a truly appealing drug-delivery strategy. Yet, results 
have been disappointing thus far, with nanoparticle-delivery of arylsulfatase (ASA) 
failing to increase cerebral enzymatic activity to a greater level than free-ASA 
application in a mouse model of MLD [63]. It has been hypothesised that the fusion of 
ASA to the particle-surface may have altered the trafficking of the particle into the 
CNS, and thus encapsulation of the enzyme within the nanoparticle may be a more 
desirable strategy. 
 
Indeed, the administration of nanoparticle-encapsulated palmitoyl-protein thioesterase 
1 (deficient in a rare lysosomal storage disorder) elevated enzymatic activity in a 
fibroblast model, with preliminary results suggesting that similar results may be seen 
for nanoparticle-formulations of GALC [64]. Yet, this study fails to truly demonstrate 
an advantage over free-enzyme administration: most notably, the use of an in vitro 
model is minimally informative about the ability of these particles to traverse the BBB.  
 
While in vivo models remain the best system in which to assess the efficacy of enzyme 
replacement, there are potential limitations to the use of some animal models in this 
context: in particular, knockout animals. As previously discussed, reintroducing 
functioning proteins into animals entirely deficient in the protein of interest—such as 
the ASA-deficient model of MLD—can trigger an immune response, as the novel 
construct is recognised as foreign [36]. Thus, future work may continue to explore 
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enzyme replacement in models with greater relevance to the human genotype: such 
as in the existing zebrafish mutants discussed above. Alternatively, genome editing 
strategies—such as those utilised to generate the GFAP knock-in model of AD—could 
also be utilised in the mouse to generate models which are not entirely deficient in the 
protein of interest: perhaps expressing a truncated or malfunctioning protein (Figure 
3). 
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Figure 3: Therapeutic strategies explored in animal models – current work and 
future directions. Schematic summarising the interactions of treatment strategies 
with leukodystrophy pathology, alongside the animal models in which they have been 
trialled. Gene therapy seeks to increase expression of functioning gene, while enzyme 
replacement therapy aims to elevate enzymatic activity. Haematopoietic stem cell 
transplant may ameliorate pathology by elevating levels of functioning enzyme, 
supporting host cells or replacing white matter components. In contrast, anti-reverse 
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transcriptase therapy may reduce substrate (nucleotide) accumulation by preventing 
reverse transcription. Future directions are suggested for each therapy. 
 
Gene therapy 
While the challenges of ERT have limited its utility in the clinic, the theoretical rationale 
still stands—elevating levels of functioning protein has the potential to improve 
pathology in leukodystrophies. Thus, gene therapy has been explored as a strategy to 
elevate protein expression within the CNS: with adeno-associated viruses (AAVs) 
largely dominating this field [65]. 
 
Preclinical studies have suggested promising results: with a recent study reporting that 
administration of a GALC-encoding AAV-vector elevated enzymatic activity to levels 
exceeding wild type in twitcher mice, accompanied by improved survival, motor 
function and even reduced CNS demyelination-rate [66]. 
 
Yet, the success of AAV-mediated gene delivery has not been ubiquitous. A similar 
study in ASA-/- mice found that delivery of AAV-vectors elicited a minimal increase in 
enzyme concentration in the cerebrospinal fluid, which decayed over the weeks 
following administration—paralleled by increasing levels of anti-human-ASA 
antibodies within the plasma [36]. Although these findings are merely correlative, this 
suggests the failure to elevate ASA was not due to a lack of genomic integration, but 
rather immune response to the novel enzyme; reflecting a key limitation of the model, 
as previously discussed.  
 
However, the variable success of these studies could also be attributed to differences 
in methodology: most notably, the time of vector application. While ASA-/- mice were 
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treated after the emergence of histological symptoms, twitcher mice were injected pre-
symptomatically with greater success: a common theme across the literature. Yet, this 
is not always feasible in patients. Due to the recessive nature of inheritance and often 
rapid progression, diagnosis may not occur until symptom presentation: limiting the 
wider utility of such interventions. Indeed, while gene therapy has led to some—albeit 
varied—positive outcomes across several leukodystrophies in clinical trials, complete 
reversal of neurological phenotypes is yet to be achieved (reviewed elsewhere [8,9]). 
 
Antisense oligonucleotide therapy 
While the therapies described above aim to elevate levels of a deficient or 
malfunctioning protein, a different strategy is required to tackle gain-of-function 
mutations – such as those seen in Alexander disease. A recent preclinical study has 
explored the use of antisense oligonucleotides—single-stranded RNA which silence 
gene expression by binding to transcripts and preventing their translation—to 
knockdown GFAP expression [15]. Strikingly, intracerebral injection of antisense 
oligonucleotides reduced levels of GFAP transcripts and protein, alongside markers 
of gliosis, across several GFAP-mutant Alexander disease mouse models. While this 
is the first study to explore the potential of such a therapy in leukodystrophy models, 
similar promise has been shown in mouse models of Huntington’s disease and 
antisense oligonucleotides have been FDA-approved for the treatment of spinal 
muscular atrophy 1 [67–69]. 
 
The main disadvantage of this approach, however, is that antisense oligonucleotides 
remain unable to cross the BBB: hence requiring invasive intracerebral or intrathecal 
injection [70]. However, injection of these constructs in early development—before the 
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formation of the BBB barrier—could overcome this limitation. While both challenging 
and dependent on prior diagnosis, in utero treatments could facilitate effective pre-
symptomatic interventions for leukodystrophies with the earliest onsets. Indeed, 
antisense oligonucleotides have been shown to effectively downregulate gene 
expression when injected into the amniotic cavity of mouse embryos in utero, or as 
routinely used into the yolk of single-cell zebrafish embryos [71,72]. Hence, antisense 
oligonucleotides may present a compelling avenue for in utero interventions. 
 
Haematopoietic stem cell transplant 
A further strategy for the treatment of leukodystrophies is haematopoietic stem cell 
transplant (HSCT). Transplantation of cells derived from the bone marrow or umbilical 
cord of healthy individuals (allogenic transplantation) is a theoretically appealing 
therapy: transplanted cells could provide source of functioning enzyme, support 
degenerating cells or even replace them functionally (Figure 3). Indeed, preclinical 
studies have suggested that transplanted cells can migrate into the CNS and 
differentiate following bone marrow transplant—both in healthy animals and mouse 
models of MLD [73–75]. 
 
However, clinical studies investigating allogenic HSCT have shown highly variable 
results. While there is some evidence that HSCT may provide a viable treatment option 
for pre-symptomatic individuals with MLD, outcomes for those treated after symptom 
presentation are much poorer [76,77]. Curiously—despite successfully rescuing ASA 
activity—HSCT fails to reliably improve pathology or symptoms: with many patients 
showing continued deterioration, albeit at perhaps a slower rate than untreated 
individuals [78–80]. 
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The potential of autologous HSCT - the transplantation of genetically-corrected cells 
derived from the patient themselves - was first highlighted in mouse models. Following 
host irradiation, transplantation at 6-weeks old of genetically-corrected haematopoietic 
stem cells derived from MLD mice led to normalisation of enzyme activity and, 
strikingly, prevention of motor and cognitive deficits, and myelin abnormalities [73].  
 
Following this preclinical success, a recent clinical trial reported that infusion of 
lentivirus-transfected haematopoietic stem cells halted disease progression in a 
modest sample of MLD patients—crucially, with no serious adverse effects [81]. 
However, given that all successfully treated patients were either pre-symptomatic or 
in the earliest stages of disease, it remains unclear whether autologous HSCT 
provides greater therapeutic efficacy than its allogenic counterpart. Nonetheless, such 
studies demonstrate the critical role of animal models in informing clinical trials. 
 
It must be noted, however, that HSCT in mice is a time-consuming and severe 
procedure—requiring irradiation or immunosuppression to minimise the probability of 
transplant rejection [82]. However, the need for these procedures is abolished if HSCT 
is performed on embryos before maturation of the adaptive immune system. While 
such interventions could be performed on mice, the zebrafish presents an ideal 
opportunity to explore HSCT in early development. Zebrafish develop transparent 
embryos ex utero with no adaptive immunity until 2 weeks of age, allowing transplant 
of foreign cells without the need of harmful irradiation procedures. Recent research 
has demonstrated that zebrafish and human primary stem cells are able to engraft 
within the haematopoietic niche of transplanted zebrafish embryos [83–86]. Hence, 
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zebrafish models may provide a simpler alternative to their murine counterparts in 
exploring the potential efficacy of HSCT in embryos (Figure 3). 
 
Anti-reverse transcriptase therapy 
While the above therapies are somewhat conventional in their approach, recent clinical 
strategies have approached the treatment of leukodystrophies from an arguably more 
obscure angle. As mentioned above, the innate immune response which underlies the 
pathology of autoimmune leukodystrophies is thought to be stimulated by endogenous 
nucleic acids incorrectly identified as non-self [24,25]. A growing body of literature has 
suggested that these immunostimulatory nucleic acids may arise from the transcription 
of endogenous retrotransposons: genetic elements which, after transcription, undergo 
reverse transcription from RNA to DNA [87].  
 
This phenomenon has been noted to be of particular relevance to AGS as several of 
the genes underpinning the disorder have been implicated in restricting reverse 
transcription (Figure 4): leading to the hypothesis that it may be possible to treat AGS 
with reverse-transcriptase inhibitors (RTIs). Indeed, the application of RTIs to human 
stem cells with TREX1 mutations was found to both decrease the level of single 
stranded RNA and reduce apoptosis [88]. However, preclinical studies have shown 
limited success. Initial findings revealed that the use of a single RTI failed to extend 
the survival of Trex1-/- mice [89], with subsequent research utilising a combination of 
RTIs also proving disappointing. While one group report that a cocktail of RTIs reduced 
mortality and cardiac inflammation in Trex1-/- mice, further research has suggested 
that RTI treatment had no such effect [90,91]. The reasons for this discrepancy are 
unclear, though it has been suggested that housing effects may be particularly 
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prominent in such studies, as the microbiome has been reported to influence activity 
of endogenous retroelements: resulting in heterogeneity in the mean survival of Trex1-
/- mice [92].  
Despite limited preclinical data, results from a small clinical trial have suggested that 
a battery of three RTIs is effective in lowering interferon signalling in AGS patients: 
indicating reduced immune activation [93]. However, no data demonstrating the effects 
on neurological symptoms have been released thus far. Likewise, issues with study 
design limit the conclusions that can be drawn from this trial—with no blinding or 
controls, a patient group of just eight and substantial heterogeneity in the patient 
interferon score both at baseline and after treatment—indicating a larger controlled 
study is necessary.  
 
Figure 4: Schematic depicting the role of AGS-associated genes in restricting 
reverse transcription. AGS-associated enzymes are proposed to limit reverse 
transcription by acting at multiple stages. SAMHD1 is thought to regulate 
retrotransposon transcription by degrading the deoxynucleotides needed for 
complementary DNA-strand formation. The ribonuclease RNaseH2 is proposed to 
degrade the RNA component of DNA-RNA hybrids formed during the reverse 
transcriptase process, while the exonuclease Trex1 is hypothesized to metabolize 
retroelement-derived nucleotides [24,89,110]. dNTP, deoxyribonucleotide 
triphosphate. 
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DNA-RNA 
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Nonetheless, these results provide an early indication that anti-reverse transcription 
therapy may present a promising clinical avenue in AGS and possible proof-of-concept 
for the role of endogenous retroelements in autoimmune conditions. Indeed, RTIs may 
have potential in treating autoimmune conditions such as systematic lupus 
erythematosus, which itself has been associated with TREX1 mutations [94]. 
Strikingly, recent findings suggest that RTIs may minimise some age-associated 
inflammatory markers in wild type mice: suggesting this therapy may show utility in 
conditions like Alzheimer’s disease, in which neuroinflammation is thought to have a 
key role [95]. However, until RTIs are tested in models of such disease, their 
translational potential remains unclear. 
 
Conclusion 
Leukodystrophies are rare but debilitating conditions characterised by white matter 
degeneration, loss of motor function and cognitive decline. Although recent decades 
have made substantial progress in understanding their pathogenesis, these disorders 
remain an unmet clinical need: with few treatments permitted for widespread clinical 
use across multiple disorders. 
 
This failure in translation is partly due to a lack of appropriate animal models of these 
disorders. By discussing the most common leukodystrophies, we have highlighted 
common weaknesses in the animal model literature—namely that the majority of 
models fail to recapitulate the key component of human disease: white matter 
pathology.  
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Likewise, poor study design limits the translation of such research. As discussed 
throughout, many preclinical studies explore pre-symptomatic intervention—a strategy 
that is not always possible in patients. Similarly, the doses utilised are often 
inappropriate for use in humans, who may require long-term treatment in order to halt 
disease progression. Furthermore—due to the rare nature of these disorders—clinical 
studies are often underpowered: using small numbers of patients or even reporting 
findings on a case-by-case basis.  
 
Additionally, it is possible that our understanding of disease mechanisms is flawed. 
The primary event for many leukodystrophies is considered to be enzymatic 
dysfunction and, as such, the end-point of many studies and therapies is normalisation 
of enzyme activity or substrate accumulation. Similarly, the accumulation of the 
relevant substrate is often deemed sufficient to consider many knockout animals 
models of leukodystrophy, despite a lack of neurological symptoms. Yet, lowering 
substrate concentration does not always halt disease progression [65,78,96]. It could 
be argued that continued degeneration is simply the result of secondary pathological 
processes—such as neuroinflammation and immune response—progressing in the 
absence of the primary event. Yet, animal models treated even before the onset of 
histological symptoms have been reported to show progressive motor impairment 
despite minimal substrate accumulation [65]. Thus, it may be time for us to reconsider 
our understanding of leukodystrophy pathogenesis and, with it, the criteria by which 
we assess our animal models—simply presenting with the relevant biochemical profile 
is no longer enough. 
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While several of the conventional therapies discussed in this review have not yet 
yielded widespread clinical results, innovative approaches to the challenges they pose 
certainly warrant further development. However therapeutic strategies and research 
that challenges our understanding of the causes of leukodystrophy are needed going 
forward. Anti-retroviral therapy is one such intervention that begins to challenge the 
framework within which we think about leukodystrophies. As such, the greatest 
therapeutic advancements may arise by asking more unconventional questions about 
the causes of these rare diseases. 
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